Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Summary

Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies.

Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and 1040 patients with mild-moderate Alzheimer’s disease, respectively, have been conducted. These clinical trials have found that Solanezumab did not improve cognition or functional ability.

Full Text Link (Note: This article requires a suitable Athens password, a journal subscription or payment for access).

Reference

Doody, RS. Thomas, RG. [and] Farlow, M. [et al] (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. New England Journal of Medicine, January 23rd 2014, Vol.370(4), pp.311-21. (Click here to view the PubMed abstract).

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.